Trial Profile
A Phase I Study of the Inhibition of LFA-1 to Intercellular Adhesion Molecule-1 (ICAM-1) Using Subcutaneous Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration (SEIRA)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Acronyms SEIRA
- 24 Oct 2014 New trial record